Epstein-Barr virus (EBV) is common and normally poses little risk to healthy people. However, EBV can cause complications in patients whose immune systems have been weakened, such as recipients of bone marrow, heart, lung, or kidney transplants. Such complications include lymphoma or other EBV-related cancers. Other people can also develop cancers related to EBV, including patients with genetic or drug-induced immune-deficiency diseases.
In this study, researchers are finding out whether giving white blood cells called T cells that are immune to EBV can be used to treat patients with EBV-related cancers and other EBV-related problems. Patients in this study include those with EBV that did not respond to standard therapy.
Patients will receive EBV-immune T cells from a bank of healthy “third-party” donors (someone not related to the patient, or a donor who previously gave blood or tissue to the patient) who are ¿partially matched¿ to the patient’s tissue type.